Epidermal growth factor receptor as a therapeutic target in colorectal cancer.

Article Details

Citation

Copy to clipboard

Cohen RB

Epidermal growth factor receptor as a therapeutic target in colorectal cancer.

Clin Colorectal Cancer. 2003 Feb;2(4):246-51.

PubMed ID

12620146 [ View in PubMed

]

Abstract

The epidermal growth factor receptor (EGFR) is widely expressed in advanced colorectal cancers (CRCs), and higher levels of EGFR are inversely related to survival in these patients. Two general strategies have been used to block EGFR signaling: preventing ligand binding with anti-EGFR monoclonal antibodies (eg, cetuximab and ABX-EGF) and inhibiting its intrinsic tyrosine kinase with small molecules (eg, gefitinib [Iressa] and erlotinib [OSI-774,Tarceva]). Phase II trials of cetuximab suggest that it might be an effective treatment option alone or in combination with standard therapies as first- or second-line therapy. Phase I studies evaluating other EGFR inhibitors in patients with CRC have been reported. The inclusion of anti-EGFR therapies into standard treatment is the subject of current clinical trials.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Panitumumab	Epidermal growth factor receptor	Protein	Humans	Yes	Suppressor	Details